+1.570 (+4.07%)
Range 38.650 - 40.510   (4.81%)
Open 38.730
Previous Close 38.610
Buy Price 40.150
Buy Volume 8
Sell Price 40.600
Sell Volume 9
Volume 808,443
Value -
Measurement Type Value
EPS (USD) -1.481
Trailing EPS (USD) -1.418
NAV (USD) 4.174
Cash In Hand (USD) 1.954
Dividend -
Dividend Yield (%) -
PE -
Trailing PE -
Price / NAV 9.692
Price / Cash In Hand 20.699
Issued & Paid-up Shares 158,855,000
Treasury Shares -
Market Cap (M) 6,425.685
Par Value (USD) n.a.
Beta - 75 Days 0.582
R-Squared - 75 Days(%) 7.85
Beta - 500 Days 0.704
R-Squared - 500 Days(%) 7.0
ISIN Code -
Under CPF Investment Scheme (CPFIS) No
Index Components
Delayed prices. Updated at 26 Sep 2020 04:00.
Data powered by

Upcoming Events

* Stock event date based on US timezone.


Release Date 10 Nov 2020
View All Events


ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. The Company has four product candidates in clinical development led by pimavanserin, which is in Phase III development as a first-in-class treatment for Parkinson's disease psychosis. It holds worldwide commercialization rights to pimavanserin. In addition, the Company has a product candidate in Phase II development for chronic pains and a product candidate in Phase I development for glaucoma, both in collaboration with Allergan, Inc., and a product candidate in Phase I development for schizophrenia in collaboration with Meiji Seika Pharma Co., Ltd. The Company's clinical-stage product candidates include Pimavanserin, Alpha Adrenergic Agonists, Muscarinic Agonist and AM-831.

Loading Chart...